The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders

Kazuaki Taguchi; Keishi Yamasaki; Hiromi Sakai; Toru Maruyama; Masaki Otagiri

doi:10.1016/j.xphs.2017.04.006

The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders

Kazuaki Taguchi, Keishi Yamasaki, Hiromi Sakai, Toru Maruyama, Masaki Otagiri

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

Bioactive gaseous molecules, such as oxygen (O₂) and carbon monoxide (CO), are essential elements for most living organisms to maintain their homeostasis and biological activities. An accumulating body of evidence suggests that such molecules can be used in clinics as a medical gas in the treatment of various intractable disorders. Recent developments in hemoglobin-encapsulated liposomes, namely hemoglobin vesicles (HbV), possess great potential for retaining O₂ and CO and could lead to strategies for the development of novel pharmacological agents as medical gas donors. HbV with either O₂ or CO bound to it has been demonstrated to have therapeutic potential for treating certain intractable disorders and has the possibility to serve as diagnostic and augmenting product by virtue of unique physicochemical characteristics of HbV. The present review provides an overview of the present status of the use of O₂- or CO-binding HbV in experimental animal models of intractable disorders and discusses prospective clinical applications of HbV as a medical gas donor.

Original language	English
Pages (from-to)	2392-2400
Number of pages	9
Journal	Journal of Pharmaceutical Sciences
Volume	106
Issue number	9
DOIs	https://doi.org/10.1016/j.xphs.2017.04.006
Publication status	Published - 2017 Sept
Externally published	Yes

Keywords

biomimetics
controlled release
liposomes
nanotechnology
particle size

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/j.xphs.2017.04.006

Cite this

@article{9e9748f4863f4bd2801ba616a3e7748c,

title = "The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders",

abstract = "Bioactive gaseous molecules, such as oxygen (O2) and carbon monoxide (CO), are essential elements for most living organisms to maintain their homeostasis and biological activities. An accumulating body of evidence suggests that such molecules can be used in clinics as a medical gas in the treatment of various intractable disorders. Recent developments in hemoglobin-encapsulated liposomes, namely hemoglobin vesicles (HbV), possess great potential for retaining O2 and CO and could lead to strategies for the development of novel pharmacological agents as medical gas donors. HbV with either O2 or CO bound to it has been demonstrated to have therapeutic potential for treating certain intractable disorders and has the possibility to serve as diagnostic and augmenting product by virtue of unique physicochemical characteristics of HbV. The present review provides an overview of the present status of the use of O2- or CO-binding HbV in experimental animal models of intractable disorders and discusses prospective clinical applications of HbV as a medical gas donor.",

keywords = "biomimetics, controlled release, liposomes, nanotechnology, particle size",

author = "Kazuaki Taguchi and Keishi Yamasaki and Hiromi Sakai and Toru Maruyama and Masaki Otagiri",

note = "Funding Information: This work was supported, in part, by Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (H24-SOUYAKUSOUGOU-IPPAN-009), by Project Promoting Clinical Trials for Development of New Drugs and Medical Devices (15Elk0201034h001) from the Japan Agency for Medical Research and Development: AMED, and by a Grant-in-Aid for Young Scientist (B) from the Japan Society for the Promotion of Science (JSPS) (KAKENHI 26860121). Publisher Copyright: {\textcopyright} 2017 American Pharmacists Association{\textregistered}",

year = "2017",

month = sep,

doi = "10.1016/j.xphs.2017.04.006",

language = "English",

volume = "106",

pages = "2392--2400",

journal = "Journal of Pharmaceutical Sciences",

issn = "0022-3549",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders

AU - Taguchi, Kazuaki

AU - Yamasaki, Keishi

AU - Sakai, Hiromi

AU - Maruyama, Toru

AU - Otagiri, Masaki

N1 - Funding Information: This work was supported, in part, by Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (H24-SOUYAKUSOUGOU-IPPAN-009), by Project Promoting Clinical Trials for Development of New Drugs and Medical Devices (15Elk0201034h001) from the Japan Agency for Medical Research and Development: AMED, and by a Grant-in-Aid for Young Scientist (B) from the Japan Society for the Promotion of Science (JSPS) (KAKENHI 26860121). Publisher Copyright: © 2017 American Pharmacists Association®

PY - 2017/9

Y1 - 2017/9

N2 - Bioactive gaseous molecules, such as oxygen (O2) and carbon monoxide (CO), are essential elements for most living organisms to maintain their homeostasis and biological activities. An accumulating body of evidence suggests that such molecules can be used in clinics as a medical gas in the treatment of various intractable disorders. Recent developments in hemoglobin-encapsulated liposomes, namely hemoglobin vesicles (HbV), possess great potential for retaining O2 and CO and could lead to strategies for the development of novel pharmacological agents as medical gas donors. HbV with either O2 or CO bound to it has been demonstrated to have therapeutic potential for treating certain intractable disorders and has the possibility to serve as diagnostic and augmenting product by virtue of unique physicochemical characteristics of HbV. The present review provides an overview of the present status of the use of O2- or CO-binding HbV in experimental animal models of intractable disorders and discusses prospective clinical applications of HbV as a medical gas donor.

AB - Bioactive gaseous molecules, such as oxygen (O2) and carbon monoxide (CO), are essential elements for most living organisms to maintain their homeostasis and biological activities. An accumulating body of evidence suggests that such molecules can be used in clinics as a medical gas in the treatment of various intractable disorders. Recent developments in hemoglobin-encapsulated liposomes, namely hemoglobin vesicles (HbV), possess great potential for retaining O2 and CO and could lead to strategies for the development of novel pharmacological agents as medical gas donors. HbV with either O2 or CO bound to it has been demonstrated to have therapeutic potential for treating certain intractable disorders and has the possibility to serve as diagnostic and augmenting product by virtue of unique physicochemical characteristics of HbV. The present review provides an overview of the present status of the use of O2- or CO-binding HbV in experimental animal models of intractable disorders and discusses prospective clinical applications of HbV as a medical gas donor.

KW - biomimetics

KW - controlled release

KW - liposomes

KW - nanotechnology

KW - particle size

UR - http://www.scopus.com/inward/record.url?scp=85019902111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019902111&partnerID=8YFLogxK

U2 - 10.1016/j.xphs.2017.04.006

DO - 10.1016/j.xphs.2017.04.006

M3 - Review article

C2 - 28414143

AN - SCOPUS:85019902111

SN - 0022-3549

VL - 106

SP - 2392

EP - 2400

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

IS - 9

ER -

The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this